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Objectives: This study describes the management of patients with bilobar colorectal liver metastases
(CRLM).
Methods: A retrospective collection of data on all patients with CRLM who were considered for staged
resection (n = 85) from January 2003 to January 2011 was performed. Patients who underwent one
hepatic resection were considered to have had a failed staged resection (FSR), whereas those who
underwent a second or third hepatic resection to produce a cure were considered to have had a
successful staged resection (SSR). Survival was calculated from the date of diagnosis of liver metastases.
Complete follow-up and dates of death were obtained from the Government of Quebec population
database.
Results: Median survival was 46 months (range: 30–62 months) in the SSR group and 22 months (range:
19–29 months) in the FSR group. Rates of 5-year survival were 42% and 4% in the SSR and FSR groups,
respectively. Fifteen of the 19 patients who remained alive at the last follow-up date belonged to the SSR
group.
Conclusions: In patients in whom staged resection for bilobar CRLM is feasible, surgery would appear
to offer benefit.
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Introduction
Approximately 142 570 Americans are diagnosed with colorectal
cancer annually.1 Of these, 51 370 will die from the disease.1 Meta-
static disease is the most common cause of death and occurs in
50% of patients.2,3
Despite improved chemotherapy with oxaliplatin, irinotecan
and the addition of biologics such as bevacizumab and cetuximab,
patients treated with palliative chemotherapy alone have a median
survival of only 18–22 months.4 Liver resection provides the only
potential for cure in patients with colorectal liver metastases
(CRLM) and 5-year survival rates as high as 60% have been
reported.5 These results have increased efforts to convert patients
with isolated hepatic disease who are initially deemed unresectable
to a technically resectable state by combining preoperative chemo-
therapy, surgery, ablative technologies, portal vein embolization
(PVE) and staged resections.5 Currently, the process of determin-
ing the resectability of a patient with CRLM focuses on the quality
and amount of liver that will be left after a negative margin (R0)
resection – the future liver remnant (FLR) – rather than the amount
of liver to be resected. All conversion strategies are aimed at leaving
an adequate FLR and depend either on increasing the size of the
FLR or on decreasing the magnitude of the hepatic resection so that
the FLR will be larger. This paradigm shift in the management of
CRLM has resulted in potentially curative resection surgery in
patients with complex bilobar liver metastases, who would previ-
ously have been deemed unresectable.
This manuscript was presented at the annual AHPBA meeting, Miami, 7–11
March 2012 and at the 10th World IHPBA Congress, Paris, 1–5 July 2012.
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A staged hepatectomy occurs when two or more liver resections
to be performed at different time-points are required to achieve an
R0 resection. The staged hepatectomy strategy takes advantage of
the liver’s ability to regenerate after injury or resection. This paper
reports on a large, single-centre experience of staged liver resec-
tion in CRLM.
Materials and methods
Patient selection
Patients with multiple bilobar CRLM that could not be completely
resected in one laparotomy were considered for staged hepatec-
tomy (Figs 1–3). Patients underwent computed tomography (CT)
of the chest, abdomen and pelvis and an 18F-fluorodeoxyglucose
positron emission tomography (18FDG PET) scan, after which
they were presented at a multidisciplinary hepatopancreatobiliary
(HPB) tumour board meeting. If a patient had liver-only disease
(with the exception of resectable lung disease) and good perfor-
mance status, and all disease could potentially be resected or
ablated using a staged approach as determined by the surgeons on
Figure 1 Computed tomography in a typical patient selected for the staged resection pathway at McGill University Health Centre
Figure 2 Computed tomography in the patient shown in Fig. 1, with
bilateral hepatic metastases, after two-stage hepatectomy, showing
hypertrophy of segment IV
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the HPB tumour board, he or she was considered for staged resec-
tion. Intraoperative ultrasound was used in all patients.
Evolution of staged hepatectomy
All patients were administered neoadjuvant chemotherapy with
FOLFIRI [folinic acid (leucovorin), fluorouracil (5-FU), irinote-
can] or FOLFOX [folinic acid (leucovorin), fluorouracil (5-FU),
oxaliplatin]. Bevacizumab was added to the regime from 2006.
Response was assessed by CT conducted between the fourth and
fifth cycles of chemotherapy. Because the authors consider an
initial response to chemotherapy an important prognostic indica-
tor, patients who did not respond to chemotherapy were excluded
from further consideration for hepatic resection.6 After the sixth
cycle, chemotherapy was discontinued for 6 weeks and the first
liver resection was performed.
The approach in managing these patients varied: (i) in some
patients, the first resection consisted of a right hepatectomy fol-
lowed by a second left-sided resection; (ii) other patients were
managed with multiple non-anatomical wedge resections to
clear one side (the FLR), followed by a second operation to
remove the contralateral liver, and (iii) in other patients a left-
sided resection was performed first and was followed by a right-
sided resection. From the middle of this series, a standard
approach was developed that could be applied to most patients.
Stage 1 of the staged hepatectomy comprised a left lateral liver
resection with or without the caudate and included the clearance
of any tumours from segment IV; this was performed laparo-
scopically if possible. The patient was allowed to recover from
stage 1 (2–3 weeks) before a right-side PVE was performed,
which was followed 4 weeks later by a CT scan to confirm an
adequate FLR. An adequate FLR was defined as a remnant
equivalent to 30% in size of the original liver because all patients
received neoadjuvant chemotherapy. If any delays occurred,
patients would receive one or two cycles of chemotherapy
without bevacizumab and then proceed to a right hepatectomy
(stage 2) followed by adjuvant chemotherapy to complete a total
of 12 cycles. This approach to staged hepatectomy was based
on preserving the middle hepatic vein (Fig. 4). This approach
ensures that growth between resections will occur in segments
IV and I, whereas if a right hepatectomy is carried out first, there
is no assurance that the increase in volume will be in segment
IV. Follow-up required the patient to attend clinic visits and to
undergo CT of the chest and abdomen and measurement of car-
cinoembryonic antigen (CEA) levels every 3 months for the first
2 years, every 6 months for the subsequent 3 years, and yearly
thereafter.
Portal vein embolization
Portal vein embolization was performed after the first hepatec-
tomy of the two-stage procedure. Embolization was performed
via an ipsilateral approach using 90–180-mm polyvinyl alcohol
(PVA) and coils to occlude segmental branch origins. In patients
undergoing right-sided embolization, the first embolization
included both the anterior and posterior sectoral branches of
the right portal vein. In general, chemotherapy was discontinued
approximately 6 weeks prior to the first hepatic resection
and the embolization was performed 2–3 weeks after the
resection.
Data collection and statistical analysis
Data on the colorectal primary pathology, date of diagnosis of
liver metastases, size of metastases, number and distribution of
metastases, operative technique and findings, and tumour board
discussion were collected using the McGill University Health
Centre (MUHC) prospective tumour registry database and by
chart review. Clinic charts and follow-up CT scans were utilized to
collect data on tumour recurrence. Morbidity was defined accord-
ing to the Clavien grade.7
Continuous variables are expressed as the median [interquartile
range (IQR)]. The date of death was confirmed in all instances of
patient death by accessing the Government of Quebec registry.
Complete follow-up to March 2012 was obtained in all patients.
Fisher’s exact test, the chi-squared test and Mann–Whitney U-test
were used as appropriate. Survival was calculated from the date of
diagnosis of liver metastasis using the Kaplan–Meier method; dif-
ferences were examined with the log-rank test. A multivariable
logistic regression analysis was used to calculate odds ratios (ORs)
with 95% confidence intervals (CIs). A P-value of <0.05 was con-
sidered to indicate statistical significance. All statistical calcula-
tions were performed using R Version 2.8.1 (R Project for
Statistical Computing; http://www.r-project.org).
Results
From January 2003 to January 2011, 85 patients with bilobar
CRLM were placed on a staged resection pathway at the Royal
Figure 3 Segment IV at the completion of two-stage hepatectomy in
a different patient
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Victoria Hospital, MUHC. The baseline characteristics of the
patients are illustrated in Table 1. Table 2 shows morbidity and
mortality in the cohort.
Two-stage hepatectomy
All patients preoperatively received a traditional chemotherapy
regimen based on 5-fluorouracil (FOLFIRI or FOLFOX); 44
patients (52%) also received bevacizumab.
Outcomes in the 85 patients considered for staged hepatectomy
following neoadjuvant chemotherapy are shown in Fig. 5. All
patients scheduled for first-stage hepatectomy underwent a major
resection (three or more segments).
Overall and recurrence-free survival
Median follow-up in the 85 patients was 31 months (IQR: 22.1–
51.2 months). At the time of last follow-up, 19 (22%) of the 85
patients placed on the staged resection pathway were alive. Rates
of overall survival at 1, 3 and 5 years were 93%, 49% and 26%,
respectively (Fig. 6). Median survival was 28.6 months (95% CI
21.0–48.6). Of the 30 patients who failed to complete the staged
resection pathway [failed staged resection (FSR) group], only four
remained alive at the last follow-up. In comparison, of the 44
patients who successfully completed the staged resection path-
way [successful staged resection (SSR) group], 15 were alive
(P < 0.001).
Median overall survival from the time of diagnosis of liver
metastases was 46 months (95% CI 30.0–62.0) in the SSR group
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Left lateral resection Right-sided hypertrophy
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IVa IVa
IVa
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Figure 4 Diagrams showing the staged resection strategy. GB, gallbladder
Table 1 Clinical and pathologic features of the study population
(n = 85)
Variable Value
Age, years, median (IQR) 57 (48–65)
Gender, male/female, n (%) 56 (66%)/29 (34%)
Node-positive primary disease, n (%) 65 (76%)
Disease-free interval of <12 months, n (%) 21 (25%)
CEA of >200 ng/ml, n (%) 13 (15%)
More than one lesion, n (%) 85 (100%)
Lesion measuring >5 cm, n (%) 15 (18%)
Synchronous lesion at 6 months, n (%) 63 (74%)
Number of lesions, median (IQR) 6 (2–14)
Size of largest lesion, cm, median (IQR) 3.4 (1–14)
Extrahepatic metastases, n (%) 11 (13%)
First-stage hepatectomy
Right-side hepatectomy, n (%) 27 (32%)
Left-side hepatectomy, n (%) 47 (55%)
Interval between surgeries, days, median (IQR) 158 (126–204)
Portal vein embolization, n (%) 48 (56%)
IQR, interquartile range; CEA, carcinoembryonic antigen.
Table 2 Morbidity according to the Clavien classification of
complications
Clavien
grade
Morbidity after first
hepatectomy, n
Morbidity after second or
third hepatectomy, n
I 3 2
II 11 11
IIIa 5 4
IIIb 2 4
IVa 1 0
IVb 0 0
V 0 0
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and 22 months (95% CI 19.0–29.0) in the FSR group (P < 0.001).
Median survival in the unresectable (no hepatectomy) patient
group was 21.6 months (95% CI 10.8–24.0).
Rates of 1-year survival were 95% in the SSR group, 93% in the
FSR group and 82% in the unresectable group (P = 0.13). Rates of
3-year survival were 68% in the SSR group, 26% in the FSR group
and 0% in the unresectable group (P < 0.001). Rates of 5-year
survival were 42% in the SSR group and 22% in the FSR group
(P = 0.011) (Fig. 6).
Factors associated with successful
staged hepatectomy
Data for the 44 patients who successfully completed the staged
resection (SSR group) were compared with data for the 30
patients in the FSR group. Univariate analysis showed that female
gender, a lower number of lesions and a largest lesion size of
<5 cm were significant factors predicting successful staged resec-
tion. Multivariable logistic regression analysis showed the pres-
ence of extrahepatic disease to be the only factor associated with
the failure of staged resection (Table 3).
Factors associated with disease-free survival
Univariate analysis showed that in the 44 patients who successfully
completed the staged resection, node-positive primary disease, a
largest lesion size of <5 cm and the presence of extrahepatic
metastasis were factors associated with lower rates of recurrence-
free survival. Multivariate logistic regression analysis (Table 4)
showed only the presence of extrahepatic disease to be associated
with lower disease-free survival.
Patients placed on the staged resection pathway between 2003 and 2011
who received neoadjuvant chemotherapy
(n = 85)
Unresectable disease,
excluded from pathway
(n = 11, 13%)
Successful completion of
first stage hepatectomy
(n = 74, 100%)
Patients planned for
second stage hepatectomy
(n = 58, 78%)
Progression of disease
(n = 16, 22%)
Portal vein embolization        (n = 48, 65%)
No portal vein embolization   (n = 10, 14%)
Unresectable disease
(n = 3, 4%)
Second stage hepatectomy
(n = 44, 59%)
Further hepatectomy
(n = 4, 5%)
Left hepatectomy (n = 47, 55%),
right hepatectomy (n = 27, 32%) or
trisegmentectomy
OR
OR
Progression of disease
(n = 1, 1%)
Medically unfit for surgery
(n = 1, 1%)
Inability to achieve
adequate FLR
(n = 2, 3%)
Failure to complete
staged resection pathway
(n = 30, 41%)
Successful completion of
staged resection pathway
(n = 44, 59%)
Figure 5 Flow chart showing the staged resection pathway in the failed and successful staged resection groups. FLR, future liver remnant
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Discussion
Staged hepatectomy for the management of bilobar CRLM is pos-
sible and appears to offer good patient survival when both resec-
tions are successfully completed. In this series, the SSR group
achieved significantly better overall and disease-free survival than
the FSR group. The staged hepatectomy was completed in 44 of 85
patients (52%), which is lower than rates reported in other
series.5,8–11 Patients entered into this pathway had been deemed
initially unresectable at presentation.
Higher success rates might be achieved if the criteria for entry
into the staged resection pathway were more restrictive. However,
in the current series, the 30 patients who failed to complete the
second resection achieved better survival than those who under-
went only exploratory laparotomy. Although these patients never
achieved a disease-free status and continued to be treated with
chemotherapy and locoregional therapy, this does not appear to
have adversely affected their overall survival rates compared with
those of patients who received palliative chemotherapy only. In
fact, perhaps because of the continued stop-and-go chemotherapy
and the locoregional therapies administered after hepatectomy in
the FSR group, survival in this group appears to have been slightly
better than that in patients receiving palliative chemotherapy
alone.4
Previous criteria to determine resectability focused on the
number and size of metastases and the chronology of the occur-
rence of liver disease in relation to that of the primary cancer,
along with the spatial arrangement of the metastases. The
Memorial Sloan–Kettering Cancer Center group refined these
criteria with a clinical risk score, which enabled the prediction
of survival after liver resection and helped to expand the
criteria for resectability by identifying a subset of patients in
whom better outcomes might be achieved.12 Adam et al.
demonstrated the feasibility of converting unresectable CRLM
patients to a potentially resectable group by using neoadjuvant
chemotherapy.8
Various researchers have focused their attention on the FLR.13
In general, an FLR equivalent to 20% of liver volume can be
viable in a normal liver resection, but, in patients who have
received chemotherapy, an FLR of  30% of hepatic volume is
recommended. Therefore, liver resection is feasible regardless of
the number and sizes of metastases as long as 30% of the liver
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Figure 6 Kaplan–Meier survival curves showing overall survival in
the successful and failed staged resection groups
Table 3 Univariate and multivariate logistic regression analysis for the success of staged resection (n = 74)
Variable Univariate analysis Multivariate analysis
OR 95% CI P-value OR 95% CI P-value
Age >65 years 0.54 0.16–1.83 0.320
Male gender 0.26 0.08–0.78 0.022 0.32 0.05–1.51 0.165
Node-positive primary disease 0.99 0.21–4.30 0.987
Disease-free interval <12 months 1.24 0.40–4.10 0.717
CEA >200 ng/ml 0.67 0.19–2.36 0.525
More than three lesions 0.40 0.10–1.30 0.148 0.29 0.05–1.42 0.145
Size of largest lesion >5 cm 0.27 0.07–0.92 0.041 0.39 0.08–1.77 0.226
Bilobar disease 0.57 0.08–2.87 0.520
Extrahepatic metastases 0.43 0.15–1.14 0.098 0.15 0.02–0.78 0.038
Interval between surgeries >150 days 0.26 0.01–2.02 0.255
OR, odds ratio; 95% CI, 95% confidence interval; CEA, carcinoembryonic antigen.
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volume can be retained and can include a draining hepatic vein
and an adequate portal and arterial supply with intact biliary
drainage.
This programme has evolved to enable all patients with pre-
dominantly liver disease to be considered as potentially resectable.
Decisions on whether patients are scheduled for extended hepa-
tectomy with or without PVE, multiple wedge resections, resec-
tion combined with local ablation, or staged hepatectomy are
based on findings in re-scanning after chemotherapy. Data from
this series and others5,8–11 indicate that the most common reason
why patients do not proceed to a second hepatic resection is that
their disease progresses during the interval between the two resec-
tions. In some patients who have been referred from other centres,
this may occur because they have already received multiple cycles
of chemotherapy prior to commencing the staged hepatectomy
protocol, whereas others may demonstrate liver regeneration
stimulated by PVE and/or the first resection.14
The only factor found to be significantly associated with the
failure of staged resection was the presence of extrahepatic
disease. Number of lesions was associated with the success of
staged hepatectomy, but showed a trend towards statistical signifi-
cance only in multivariate analysis. This finding is similar to data
reported in previous studies showing that age and the presence of
three or more metastases in the FLR were associated with staged
hepatectomy failure.10
The current study has demonstrated the feasibility and safety of
the staged hepatectomy strategy, as well as its ability to achieve a
cure and improve overall and disease-free survival. The present
findings are strengthened by the size of the series and the complete
survival data obtained from the provincial death registry. Weak-
nesses of the present study include those inherent in a largely
retrospective study design and the fact that multivariate analysis
was performed using data for a relatively low number of patients.
In conclusion, staged hepatectomy is a feasible and safe technique
for the management of bilobar CRLM. When staged hepatectomy
is successfully completed, 5-year survival exceeds 40%. This strat-
egy can be used in patients for whom maintaining an adequate
FLR would not be possible in a single resection. For this patient
population, staged resection may represent the only chance for
cure. Future studies should focus on comparative investigations of
outcomes in patients in whom staged resection is not attempted,
and on the quality of life of patients undergoing aggressive resec-
tional interventions. In addition, future studies should be directed
at defining the role of chemotherapy between resections.
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